

Regd. Off: Bhartiagram, Gajraula, Distt.Jyotiba Phoolay Nagar-244 223 (U.P)

Audited Financial Results for the Year ended 31st March, 2006

(Rs in Million)

CONSOLIDATED RESULTS					Particulars	JUBILANT ORGANOSYS LTD.				
9 Months Ended	Quarter Ended		Year Ended			9 Months Ended	Quarter Ended		Year Ended	
December 31	March 31		March 31			December 31	March 31		March 31	
(Unaudited)	(Unaudited)		(Audited)			(Unaudited)	(Unaudited)		(Audited)	
2005	2006	2005	2006	2005	2005	2006	2005	2006	2005	
7765	2527	2249	10292	8536	Domestic sales & services	7765	2527	2249	10292	8536
3942	2009	1234	5951	4201	International sales	3293	1464	1124	4757	3644
11707	4536	3483	16243	12737	Gross sales	11058	3991	3373	15049	12180
(891)	(298)	(268)	(1189)	(1034)	Less: Excise duty on Sales	(891)	(298)	(268)	(1189)	(1034)
10816	4238	3215	15054	11703	Net sales	10167	3693	3105	13860	11146
101	96	110	197	166	Other income	89	88	107	177	139
10917	4334	3325	15251	11869	Total income	10256	3781	3212	14037	11285
9339	3545	2802	12884	9627	Total expenditure	8646	3011	2683	11657	9221
(134)	(52)	42	(186)	(388)	a) (Increase)/Decrease in stock of manufactured goods	(24)	(87)	57	(111)	(249)
382	61	36	443	258	b) Cost of trading goods sold	371	32	33	403	252
5261	1881	1660	7142	5701	c) Raw & process materials consumed	5176	1837	1644	7013	5643
538	222	163	760	607	d) Stores, spares, chemicals, catalyst & packing material consumed	507	199	154	706	579
897	265	242	1162	1023	e) Manufacturing expenses	897	265	242	1162	1023
321	114	80	435	372	- Cost of power & fuel	310	108	78	418	350
879	480	215	1359	807	f) Staff cost	557	214	171	771	671
1195	574	364	1769	1247	g) Selling, general & admin. expenses	852	443	304	1295	952
1578	789	523	2367	2242	Operating profit before interest and depreciation	1610	770	529	2380	2064
143	30	48	173	220	Interest (Net)	128	19	44	147	213
1435	759	475	2194	2022	Operating profit before depreciation	1482	751	485	2233	1851
358	155	94	513	381	Depreciation	314	128	90	442	348
1077	604	381	1681	1641	Profit before tax	1168	623	395	1791	1503
256	136	41	392	431	Provision for tax (including deferred tax & Fringe Benefits tax and net of reversals)	254	149	35	403	370
821	468	340	1289	1210	Net profit after tax	914	474	360	1388	1133
6	(14)	(3)	(8)	18	Minority Interest	-	-	-	-	-
815	482	343	1297	1192	Net profit after Minority Interest	914	474	360	1388	1133
140.3	142.5	129.6	142.5	129.6	Paid-up share capital (Face value of the share is Re.1)	140.3	142.5	129.6	142.5	129.6
			8115	4887	Reserves (excluding revaluation reserve)				8102	4803
6.03	3.52	2.84	9.48	9.88	Earnings per share (Not annualized)	6.76	3.47	2.98	10.15	9.39
5.45	3.17	2.69	8.57	9.35	Basic (Rs.)	6.11	3.12	2.82	9.17	8.90
					Diluted (Rs.)					
66122525	68452650	55422930	68452650	55422930	Aggregate of non-promoter shareholding	66122525	68452650	55422930	68452650	55422930
47.14	48.06	42.78	48.06	42.78	- Number of shares (Re 1 each)	47.14	48.06	42.78	48.06	42.78
					- Percentage of shareholding					

NOTES :

1. During the quarter, each equity share of Rs.5 was sub-divided into 5 equity shares of Re.1 each. As on 31st March 2006, the number of equity shares were 142,442,995. EPS and number of shares for the periods/previous year has accordingly been restated.

2.(a) The Company issued 1.5% Foreign Currency Convertible Bonds (FCCB 2009) amounting to US\$ 35 million in May 2004. During the quarter, US\$ 7.95 million worth of Bonds had been converted into Equity Shares resulting in allotment of 2,176,625 equity shares of Re 1 each. Accordingly, Paid-up Share Capital increased by Rs.2.18 million and Securities Premium by Rs.354.02 million. As on 31st March 2006, US\$5.55 million worth of FCCB 2009 were outstanding

(b) The Company issued Zero Coupon Foreign Currency Convertible Bonds (FCCB 2010) amounting to US\$ 75 million in May 2005, which were outstanding as on 31st March 2006. Out of this amount, US\$ 55.5 million has been utilized for capital expenditure, Investment in subsidiary companies for acquisitions and other permitted uses and the Balance of US\$ 19.5 million has been kept in deposit in overseas bank account.

3. The Company has granted 594,391 options under Jubilant Employees Stock Option Plan 2005 as per SEBI guidelines to eligible directors (other than promoter directors) and other specified categories of employees of the company/ subsidiaries. Each option, upon vesting, shall entitle the holder to subscribe to one equity share of Rs.5. As a result of sub-division as stated in Note no 1 above, each option shall entitle the holder to five equity shares of Re 1 each.

4. The Board has recommended a dividend of Rs. 1.25 per equity share of Re. 1, totalling to Rs. 203.03 million, subject to approval in Annual General Meeting.

5. Consolidated results include results for subsidiary companies, namely, Jubilant Pharma N.V., Pharmaceutical Services Incorporated N.V., PSI Supply N.V., Jubilant Pharma Pte. Ltd., Trigen Laboratories, Inc., Jubilant Pharmaceuticals, Inc., Clinsys Holdings, Inc., Clinsys, Inc., Jubilant Organosys (USA), Inc., Jubilant Organosys (Shanghai) Ltd., Jubilant Biosys Ltd., Jubilant Chemsys Ltd. and Jubilant Clinsys Ltd.

6. Segment revenue, results and capital employed include the respective amounts identifiable to each of the segments and allocated on reasonable basis. Other Unallocable Expenditure includes expenses incurred on common services, provided to the segments which are not directly allocable on an appropriate basis

7. Information on investors complaints for the quarter (nos.): Opening Balance – Nil New – 50 Disposals – 50 Closing Balance – Nil

8. Figures for previous period / year have been regrouped / reclassified / restated, wherever necessary.

9. The above Financial Results were taken on record by the Board of Directors at the meeting held on 18th April 2006.

Place : Noida

Dated : 18th April, 2006

For Jubilant Organosys Ltd

Shyam S Bhartia
Chairman & Managing Director